Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Feb 11, 2026
NVO vs NVS Stock Comparison: Q4 2025 Earnings Recap and Outlook

NVO vs NVS Stock Comparison: Q4 2025 Earnings Recap and Outlook

Key Takeaways

  • Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected.

  • Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures.

  • Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.

  • NVS reached a 40% core margin ahead of schedule, while 2026 forecasts show low single-digit growth in net sales and a slight decline in core operating income amid patent expirations.

  • Key growth drivers: NVO’s obesity care surged 31% to DKK 82.3B (Wegovy), NVS saw Kisqali jump 57% to $4.8B.

  • Both companies face U.S. pricing and competitive pressures, but NVS demonstrates margin resilience, whereas NVO focuses on high-volume growth.

Earnings Context: Why This Comparison Matters

Novo Nordisk’s Q4 results underscore its leadership in GLP-1 therapies like Wegovy and Ozempic. Despite slowing U.S. demand and pricing cuts, NVO delivered 10% FY sales growth, though 2026 guidance is cautious.

In contrast, Novartis provides a lens into diversified pharma resilience. NVS posted steady growth despite generic erosion on Entresto and reached margin targets early. With obesity treatments maturing and oncology/immunology competition intensifying, investors must balance NVO’s high-growth but volatile trajectory against NVS’s stability in a competitive biotech landscape.

Novo Nordisk (NVO) Earnings Highlights

  • Q4/FY 2025 results (Feb 4, 2026):

    • Q4 EPS: $1.02 (+$0.10 vs consensus)

    • Revenue: $12.53B (+4.5% vs $11.99B expected)

  • Full-year 2025:

    • Sales: DKK 309.1B, up 10% at CER

    • Obesity care: DKK 82.3B, up 31%, led by Wegovy

    • Gross margin: 81%, slightly down due to pricing

  • 2026 guidance: Adjusted sales and operating profit projected -5% to -13% at CER (excluding 340B reversal), reflecting U.S. pricing pressure and competition.

  • Market reaction: Stock dropped ~15% post-earnings on cautious outlook.

Novartis (NVS) Earnings Highlights

  • Q4/FY 2025 results (Feb 4, 2026):

    • Q4 core EPS: $2.03 vs $1.99 estimate

    • Net sales: $13.34B (-1% cc, impacted by Entresto generics)

  • Full-year 2025:

    • Net sales: +8%

    • Core operating income: +14% to CHF 21.9B

    • Core EPS: +17% to $8.98

    • Core margin: 40.1%, reached ahead of schedule

  • Key growth driver: Kisqali (+57% to $4.8B)

  • 2026 outlook: Net sales expected in low single digits, core operating income slightly down due to patent expirations.

  • Market reaction: Shares rose on strong execution and margin discipline.

Earnings Comparison and Market Insights

  • Growth drivers:

    • NVO: Obesity care (Wegovy) 31%

    • NVS: Kisqali/Cosentyx mid-teens growth

  • Margin and risk profile:

    • NVO: Volume-focused, margins pressured by pricing

    • NVS: Diversified, oncology/cardio offsetting patent losses

  • Investor sentiment:

    • NVS favored for stability and strong margin execution

    • NVO seen as higher-risk, high-growth, with volatility linked to pricing resets and U.S. competition

AI Trading Bot Perspective

Tickeron’s AI-driven bots, such as the Trend Trader for Beginners Strategy for Large Cap Stocks (60-min TA), track momentum in large-cap stocks like NVO and NVS using 60-minute technical analysis. Backtested for volatile sectors, these bots help investors identify entry and exit points in healthcare equities.

Current Tickeron AI assessment:

  • Favored stock: NVS

  • Rationale: Superior earnings quality, achieved margins amid headwinds, balanced growth outlook, and lower volatility. NVS also offers dividend appeal in a maturing GLP-1 market, while NVO faces a pricing reset and high exposure to metabolic therapies

    Disclaimers and Limitations

Related Ticker: NVO, NVS

NVO's RSI Oscillator ascends from oversold territory

The RSI Oscillator for NVO moved out of oversold territory on March 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In of the 21 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where NVO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on March 09, 2026. You may want to consider a long position or call options on NVO as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NVO just turned positive on March 09, 2026. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .

NVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

NVO moved below its 50-day moving average on February 03, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NVO crossed bearishly below the 50-day moving average on February 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NVO entered a downward trend on March 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.688) is normal, around the industry mean (9.327). P/E Ratio (10.783) is within average values for comparable stocks, (22.671). Projected Growth (PEG Ratio) (4.707) is also within normal values, averaging (2.276). NVO has a moderately high Dividend Yield (0.045) as compared to the industry average of (0.025). P/S Ratio (3.574) is also within normal values, averaging (3.947).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NYSE:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 112.62B. The market cap for tickers in the group ranges from 72.83K to 909.04B. LLY holds the highest valuation in this group at 909.04B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -5%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 10%. SCLX experienced the highest price growth at 3%, while MDCX experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 42%. For the same stocks of the Industry, the average monthly volume growth was -92% and the average quarterly volume growth was -83%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 30
P/E Growth Rating: 66
Price Growth Rating: 55
SMR Rating: 55
Profit Risk Rating: 73
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
NVO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. NVO showed earnings on February 03, 2026. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Novo Alle 1
Phone
+45 44448888
Employees
64319
Web
https://www.novonordisk.com
Interact to see
Advertisement
Financial Learning Models (FLMs) and machine learning (ML) to operate at unprecedented speeds. These agents, now optimized for 5-minute (M5) timeframes, have demonstrated extraordinary annualized returns, with the top agent exceeding +160%.
AI-Driven Market Insights A.I.dvisor’s latest analysis compares SPY and VOO, two leading ETFs, revealing near-identical year-to-date (YTD) gains of 9.82% for SPY and 9.87% for VOO, a 99% parity.
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents. These innovative brokerage agents provide real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced groundbreaking results from its AI Trading Agents, showcasing exceptional performance in real-time trading signals powered by machine learning. Utilizing tick-level brokerage data and precise trade amounts, these agents operate on 5-, 15-, and 60-minute timeframes to provide traders with actionable insights in volatile markets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents. These cutting-edge brokerage agents deliver real-time trading signals powered by machine learning, leveraging tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes. Designed to empower traders with superior insights, the agents have demonstrated exceptional performance, including annualized returns as high as 82%.
#artificial_intelligence
The financial markets have undergone a profound transformation in recent years, driven by the integration of artificial intelligence (AI) into trading strategies. As a financial analyst, writer, and AI specialist, one observes that AI trading agents represent a pinnacle of this evolution, blending machine learning algorithms with real-time data analysis to execute trades with unprecedented precision.
#artificial_intelligence
AI trading represents a revolutionary shift in how financial markets operate, combining artificial intelligence, machine learning, and sophisticated algorithmic trading strategies to execute trades with unprecedented precision and speed.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced exceptional trading results from its AI Trading Agent focused on Hubbell Incorporated (HUBB). The agent, operating on a 5-minute timeframe, delivered a +105% annualized return, starting from an initial balance of $100,000.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents, delivering real-time trading signals and sophisticated money management for retail and institutional traders. Powered by Financial Learning Models (FLMs) and machine learning, these agents operate across 5-, 15-, and 60-minute timeframes, achieving annualized returns of up to 145% on select portfolios.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the exceptional performance of its AI Trading Agents, achieving annualized returns of up to 162%, profitable trade percentages as high as 90.51%, and a robust profit factor across multiple assets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, proudly announces the exceptional performance of its AI Trading Agents, delivering annualized returns of up to 188% on a 5-minute timeframe.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced the launch of its advanced Pattern Search Engine (PSE), a revolutionary platform that scans 39 distinct trading patterns across stocks, penny stocks, ETFs, crypto, and forex.
#artificial_intelligence
AI trading bots represent the pinnacle of financial technology innovation, transforming how traders and investors interact with global markets.
#artificial_intelligence
As a financial analyst, writer, and AI specialist, I've always pushed for innovations that merge artificial intelligence with actionable trading tools. In the fast-paced world of modern markets, where volatility demands quick decisions, Tickeron's new "My Trades Aggregator (from AI Robots Followed)" aggregator stands out as a revolutionary feature.
#artificial_intelligence#trading
Tickeron, a leading provider of AI-driven trading solutions, is thrilled to announce the exceptional performance of its AI Trading Agents, delivering outstanding results across multiple high-profile stocks.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technologies, today announced groundbreaking results from its AI Crypto Trading Virtual Agents. These innovative tools provide real-time trading signals, integrated money management, and customizable balances, all powered by advanced machine learning algorithms operating on 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technologies, today announced the launch of its advanced AI Trading Brokerage Agents. These cutting-edge tools deliver real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
This remarkable rally represents far more than typical market volatility – it signals a fundamental transformation in investor sentiment toward AI connectivity infrastructure and the critical role of semiconductor-based solutions in enabling next-generation artificial intelligence systems
Tickeron, a leader in AI-driven financial tools, today announced the launch of its comprehensive subscription package combining AI Trading Robots for cryptocurrencies with Real-Time Patterns (RTP) analysis.
#artificial_intelligence
Kinross Gold Corporation (KGC), a leading Canada-based gold producer, yielded approximately 2.1 million gold equivalent ounces in 2024.
#artificial_intelligence